Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer

Gynecologic Oncology

Volumn 77, Issue 2, 2000, Pages 258-263

  Konecny, Gottfried ^a   Crohns, Corinna ^b   Pegram, Mark ^a   Felber, Margret ^b   Lude, Sandra ^b   Kurbacher, Christian ^c   Cree, Ian A ^d   Hepp, Herrmann ^b   Untch, Michael ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ATP; Chemosensitivity; Drug resistance; Ovarian cancer; Prediction

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; PACLITAXEL;

ANALYTIC METHOD; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG SENSITIVITY; FEMALE; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RELIABILITY; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0034109492     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5728     Document Type: Article

References (16)

1. Sevin B U, Perras J P, Averette H E, Donato D M, Penalver M. Chemosensitivity testing in ovarian cancer. Cancer. 71:1993;1613-1620.
2. Bellamy W T. Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs. 44:1992;690-708.
3. Andreotti P E, Cree I A, Kurbacher C M, Hartmann D M, Linder D, Harel G, Gleiberman I, Caruso P A, Ricks S H, Untch M, Sartori C, Bruckner H W. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian cancer. Cancer Res. 55:1995;5276-5282.
4. Sevin B U, Peng Z L, Perras J P, Ganjei P, Penalver M, Averette H E. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol. 31:1988;191-204.
5. Gormley P E, Bull J M, LeRoy A F, Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther. 25:1979;351-357.
6. Harland S J, Newell D R, Siddik Z H, Chadwick R, Calvert A H, Harrap K R. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res. 44:1984;1693-1697.
7. Robert J, Illiadis A, Hoerni B, Cano J P, Durand M, Lagarde C. Pharmacokinetics of Adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol. 18:1982;739-745.
8. Wiernik P H, Schwartz E L, Strauman J J, Dutcher J P, Lipton R B, Paietta E. Phase I clinical and pharmacokinetic study of Taxol. Cancer Res. 47:1987;2486-2493.
9. Gynecol Obstet. 35:1988;125-127.
10. Cree I A, Kurbacher C M, Untch M, Sutherland L A, Hunter E M, Subedi A MC, James E A, Dewar J A, Preece P E, Andreotti P E, Bruckner H W. Correlation of clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs. 7:1996;630-635.
11. Kurbacher C M, Cree I A, Bruckner H W, Brenne U, Kurbacher J A, Muller K, Ackermann T, Gilster T J, Wilhelm L M, Engel H, Mallmann P K, Andreotti P E. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs. 9:1998;51-57.
12. Omura G A, Bundy B N, Berek J S, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 7:1989;457-465.
13. McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
14. Pfisterer J Weber B, Du Bois A, Goupil A, Meier W, Mousseau M, Kuhn W, Richter B. France: Epirubicin/paclitaxel/carboplatin vs. paclitaxel/carboplatin as first-line treatment in ovarian cancer: results of a safety interim analysis of the AGO-GINECO intergroup trial. Proc Am Soc Clin Oncol. 18:1999;367a.
15. Markman M. Recurrence within 6 months of platinum therapy: an adequate definition of platinum refractory ovarian cancer, editorial. Gynecol Oncol. 69:1998;91-92.
16. Sevin B U, Perras J P. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer. Am J Obstet Gynecol. 176:1997;759-766.